Pulse Biosciences (PLSE) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.28
- Estimate
- -$0.28
- Surprise
- +1.5%
- Revenue (period 2026-06-30)
- $434,000
- Score today
- 4.5/10
Revenue source: xbrl.
How the report landed
Pulse Biosciences (PLSE) reported diluted EPS of -$0.28, in line with the -$0.28 estimate.
Where TrendMatrix's rating stands now
TrendMatrix currently rates PLSE Sell at 4.5/10; no pre/post engine snapshot brackets this report.
2 of the last 4 quarters beat the estimate; this quarter's +1.5% surprise compares with a +3.1% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Target reached (-16.8% upside)
- Quality below floor (1.8 < 4.0)
- Value-trap signals (2/5): Revenue declining (-22.6% YoY), Negative free cash flow
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $52.11
- Price target
- $57.72
- Stop
- $49.39
- Upside to target
- +10.8%
Model outputs from TrendMatrix’s engine as of 2026-09-14 — shown for context, not personalized investment advice.
PLSE at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Medical Instruments & Supplies
- Market cap
- $3.79B
- P/E (fwd)
- -46.0
- 52-week range
- $12.56–$58.90
- Off 52-week high
- 11.5%
- RSI (14)
- 56
- Volume vs avg
- 1.10×
- Score today
- 4.5/10